AGA technical review on obesity

Gastroenterology

Volumn 123, Issue 3, 2002, Pages 882-932

  Klein, Samuel ^a,b,c   Wadden, Thomas ^a,b,c   Sugerman, Harvey J ^a,b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; ANOREXIGENIC AGENT; BENZPHETAMINE; LONAMIN; MAZINDOL; METHAMPHETAMINE; OBY TRIM; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PRELU 2; RESIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; X TROZINE;

BEHAVIOR MODIFICATION; BODY FAT; BODY MASS; CANCER; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COMORBIDITY; DIET THERAPY; DRUG INDUCED DISEASE; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GALLBLADDER DISEASE; GASTROINTESTINAL DISEASE; GASTROPLASTY; GENETIC RISK; HIGH RISK POPULATION; HUMAN; INSOMNIA; LUNG DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STOMACH BYPASS; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0036724935     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.35514     Document Type: Article

References (504)

1. Annual deaths attributable to obesity in the United States
2. Current estimates of the economic cost of obesity in the United States
3. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report
4. Nutrition and overweight
5. Health percentage body fat ranges: An approach for developing guidelines based on body mass index
6. The relationship between body weight and mortality: A quantitative analysis of combined information from existing studies
7. Body-mass index and mortality in a prospective cohort of U.S. adults
8. Body weight and mortality among women
9. The effect of age on the association between body-mass index and mortality
10. Losing weight - An ill-fated New Year's resolution
11. The degree of masculine differentiation of obesities: A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculus disease
12. Relation of body fat distribution to metabolic complications of obesity
13. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indices of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women
14. Weight, weight change, and coronary heart disease in women: Risk within the "normal" weight range
15. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men
16. Weight gain as a risk factor for clinical diabetes mellitus in women
17. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men
18. Body weight, weight change, and risk for hypertension in women
19. Weight, diet, and risk of symptomatic gallstones in middle-aged women
20. The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men
21. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men
22. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians
23. Inhibition of food intake by inhibitors of fatty acid synthase
24. Overweight and obesity in the United States: Prevalence and trends, 1960-1994
25. Obesity as a medical problem
26. Changes in the distribution of body mass index of adults and children in the US population
27. Obesity evaluation and treatment: Expert Committee recommendations
28. Do obese children become obese adults?
29. Body mass index during childhood, adolescent and young adulthood in relation to adult overweight and adiposity: The Fels Longitudinal Study
30. Obesity
31. Genetics of obesity
32. The human obesity gene map: The 2001 update
33. Congenital leptin deficiency is associated with severe early-onset obesity in humans
34. A leptin missense mutation associated with hypogonadism and morbid obesity
35. Effects of recombinant leptin therapy in a child with congenital leptin deficiency
36. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction
37. Obesity and impaired prohormone processing associated with mutation of the human prohormone convertase 1 gene
38. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans
39. Dominant and recessive inheritance of morbid obesity associated with melanocortin-4 receptor deficiency
40. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation
41. Temporal trends in energy intake in the United States: An ecologic perspective
42. Determinants of weight gain and overweight in adult Finns
43. Obesity in Britain: Gluttony or sloth?
44. Divergent trends in obesity and fat intake patterns: The American paradox
45. Gene-environment interactions in the pathogenesis of type 2 diabetes mellitus: Lessons learned from the Pima Indians
46. An investigation of nutrition-related risk factors in an isolated Aboriginal community in Northern Australia: Advantages of a traditionally-orientated life style
47. Marked improvement in carbohydrate and lipid metabolism in diabetic Australian Aborigines after temporary reversion to traditional lifestyle
48. Weight in infancy and death from ischaemic heart disease
49. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): Relation to reduced fetal growth
50. Birthweight and adult health outcomes in a biethnic population in the USA
51. Thinness at birth and insulin resistance in adult life
52. The fetal origins of diseases of old age
53. Does breast-feeding protect against childhood obesity?
54. Breast feeding and obesity: Cross sectional study
55. Predicting obesity in young adulthood from childhood and parental obesity
56. Twenty-four-hour energy expenditure and resting metabolic rate in obese, moderately obese, and control subjects
57. Impact of body fat mass and percent fat on metabolic rate and thermogenesis in men
58. The thermic effect of food and obesity: A critical review
59. Thermic effect of food during graded exercise in normal weight and obese men
60. Energy expenditure in lean and obese prepubertal children
61. Energy expenditure and physical fitness in overweight vs non-overweight prepubertal girls
62. Normal levels of energy expenditure in patients with reported "low metabolism.
63. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects
64. Energy expenditure and intake from infants born to lean and overweight mothers
65. Parental body composition and infant energy expenditure
66. Energy intake, not energy output, is a determinant of body size in infants
67. Reduced rate of energy expenditure as a risk factor for body-weight gain
68. Fasting respiratory exchange ratio and resting metabolic rate as predictors of weight gain: The Baltimore Longitudinal Study on Aging
69. The response to long-term overfeeding in identical twins
70. Role of nonexercise activity thermogenesis in resistance to fat gain in humans
71. Is obesity due to a heritable difference in "set point" for adiposity?
72. Long-term effects of dieting on resting metabolic rate in obese outpatients
73. Total resting energy expenditure in obese women reduced to ideal body weight
74. Do adaptive changes in metabolic rate favor weight regain in weight-reduced individuals? An examination of the set-point theory
75. Meta-analysis of resting metabolic rate in formerly obese subjects
76. Cellularity of obese and non-obese human adipose tissue
77. Survival during fasting may depend on fat as well as protein stores
78. Features of a successful therapeutic fast of 382 days duration
79. Exercise-training enhances fat-free mass preservation during diet-induced weight loss: A meta-analytical finding
80. Influence of diet and exercise on skeletal muscle and visceral adipose tissue in men
81. Visceral adipose tissue: A critical review of intervention strategies
82. Effect of weight reduction on in vitro adipose tissue lipolysis and cellularity in obese adolescents and adults
83. Fat cell weight and number before and after gastric surgery for morbid obesity in women
84. Regulation of adipose cell number in man
85. Apoptosis of human adipocyte in vitro
86. Human adipocyte apoptosis occurs in malignancy
87. Medical hazards of obesity
88. Overweight, obesity, and health risk
89. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma
90. Risk factors associated with symptoms of gastroesophageal reflux
91. The prevalance of symptoms suggestive of esophageal disorders
92. Epidemiology of upper dyspepsia in a random population
93. Prevalence of symptoms suggestive of gastroesophageal reflux disease in an adult population
94. No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study
95. Lower esophageal sphincter pressure (LESP) and esophageal function in obese humans
96. Gastroesophageal reflux and obesity
97. Does massive obesity promote abnormal gastroesophageal reflux?
98. Obesity correlates with gastroesophageal reflux
99. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight
100. Gastroesophageal reflux in obese patients is not reduced by weight reduction
101. Twenty-four hour pH measurements in morbid obesity: Effects of massive overweight, weight loss and gastric distension
102. Roux-en Y gastric bypass: An effective antireflux procedure
103. Roux-en Y gastric bypass: An effective antireflux procedure in the less than morbidly obese
104. Symptomatic and clinical improvement in morbidly obese patients with gastroesophageal reflux disease following Roux-en Y gastric bypass
105. Gastro-oesophageal reflux before and after vertical banded gastroplasty in the treatment of obesity
106. Vertical banded gastroplasty or gastric banding for morbid obesity: Effects on gastro-oesophageal reflux
107. Stomal ulcer after gastric bypass
108. Obesity
109. Risk of symptomatic gallstones in women
110. Gallstones, serum lipids and glucose tolerance among male officials of Self-Defense Forces in Japan
111. Overweight and obesity in middle-aged British men
112. Pathophysiology and pathogenesis of cholesterol gallstone formation
113. Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile gallstones during loss of weight
114. Gallstone formation during weight-reduction dieting
115. Risk factors for gallstone formation during rapid loss of weight
116. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program
117. Prevalence and treatment of gallstones after gastric bypass surgery for morbid obesity
118. The effect ursodeoxycholic acid therapy on gallstone formation in the morbid obese during rapid weight loss
119. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss
120. Gallstone formation after rapid weight loss: A prospective study in patients undergoing gastric bypass surgery for treatment of morbid obesity
121. Medically safe rate of weight loss for the treatment of obesity: A guideline based on risk of gallstone formation
122. Gallbladder emptying stimuli in obese and normal weight subjects
123. Gallbladder motility and gallstone formation in obese patients following very low calorie diets. Use it (fat) to lose it (well)
124. Reduced risk of liver-function-test abnormalities and new gallstone formation with weight loss on 3350-kJ (800-kcal) formula diets
125. Gallstone formation in obese women treated by a low-calorie diet
126. Obesity and risk of gallstone development on a 1200 kcal/d (5025 kJ/d) regular food diet
127. The role of gallbladder emptying in gallstone formation during diet-induced rapid weight loss
128. Similarity in gallstone formation from 900 kcal/day diets containing 16 g vs 30 g of daily fat
129. Estimation of the cost savings resulting from the use of ursodiol for the prevention of gallstones in obese patients undergoing rapid weight reduction
130. Obesity: An important prognostic factor in acute pancreatitis
131. Obesity: A risk factor for severe acute biliary and alcoholic pancreatitis
132. Is obesity a significant prognostic factor in acute pancreatitis?
133. Increased body weight as a prognostic parameter for complications in the course of acute pancreatitis
134. Obesity: A prognostic factor of severity in acute pancreatitis
135. Obesity as a predictor of severity in acute pancreatitis
136. Fatty liver hepatitis and cirrhosis in obese patients
137. Nonalcoholic fatty liver disease: A spectrum of clinical pathological severity
138. Effect of rapid weight loss with supplemented fasting on liver tests
139. Safety and effectiveness of weight reduction using a very-low calorie formulated food
140. Liver fibrosis in overweight patients
141. Nonalcoholic steatohepatitis
142. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors
143. Liver abnormalities in severely obese subjects: Effect of a drastic weight loss after gastroplasty
144. Prevalence of and risk factors for hepatic steatosis in Northern Italy
145. Nonalcoholic steatohepatitis
146. Metabolic and nutritional considerations in nonalcoholic fatty liver
147. Nonalcoholic steatohepatitis
148. Excess weight risk factor for alcoholic liver disease
149. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis
150. Association of nonalcoholic fatty liver disease with insulin resistance
151. Association between hepatic steatosis, insulin resistance and hyperinsulinemia as related to hypertension in alcohol consumers and obese people
152. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men. Role of the metabolic syndrome
153. Steatohepatitis: A tale of two "hits
154. Cytokines in alcoholic and nonalcoholic steatohepatitis
155. Effect of weight reduction on hepatic abnormalities in overweight patients
156. Nonalcoholic steatohepatitis in obesity: A reversible condition
157. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity
158. Hepatic effects of dietary weight loss in morbidly obese subjects
159. Fasting in obesity: Another cause of liver injury with alcoholic hyaline?
160. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1
161. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?
162. The metabolically obese, normal-weight individual revisited
163. Role of insulin resistance in human disease
164. Risk variable clustering in the insulin resistance syndrome
165. Relationship of generalized and regional adiposity to insulin sensitivity in men
166. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM
167. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat
168. Visceral obesity in men: Associations with glucose tolerance, plasma insulin and lipoprotein levels
169. Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men
170. Does intra-abdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive?
171. Visceral fat and insulin resistance-causative or correlative?
172. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994
173. Weight as a risk factor for clinical diabetes in women
174. The influence of body fat distribution on the incidence of diabetes mellitus
175. Adiposity and adipose tissue distribution in relation to incidence of diabetes in women: Results from a prospective population study in Gothenburg, Sweden
176. Increased incidence of diabetes mellitus in relation to abdominal adiposity in older women
177. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles
178. Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population
179. Regional adiposity pattern in relation to lipids, lipoprotein cholesterol, and lipoprotein subfraction mass in men
180. Body mass index and the prevalence of hypertension and dyslipidemia
181. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM Experience)
182. The small, dense LDL phenotype and the risk of coronary heart disease: Epidemiology, patho-physiology and therapeutic aspects
183. Is relationship between serum cholesterol and risk of premature death from coronary disease continuous or graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
184. Abdominal adiposity and coronary heart disease in women
185. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study
186. American Heart Association call to action: Obesity as a major risk factor for coronary heart disease
187. AHA Dietary guidelines revision 2000: A statement for healthcare professionals from the nutrition committee of the American Heart Association
188. Body size and fat distribution as predictors of stroke among US men
189. A prospective study of body mass index weight change, and risk of stroke in women
190. Deep venous thrombosis and pulmonary embolism
191. Risk factors for chronic venous insufficiency: A dual case-control study
192. Smoking and abdominal obesity. Risk factors for venous thromboembolism among middle-aged men: "The study of men born in 1913
193. Abdominal pressure, sagittal abdominal diameter and obesity co-morbidity
194. Elevated C-reactive protein levels in overweight and obese adults
195. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty
196. Weight and blood pressure. Findings in hypertension screening of 1 million Americans
197. The relation of adiposity to blood pressure and development of hypertension. The Framingham study
198. Obesity, alcohol consumption and blood pressure in Australian men and women: National Heart Foundation of Australia Risk Factor Prevalence Study
199. Obesity and hypertension: Experimental data
200. Body fat patterning and blood pressure in children and young adults: The Bogalusa Heart Study
201. Relationship of body fat distribution to blood pressure, carbohydrate tolerance, and plasma lipids in healthy obese women
202. Obesity and pulmonary function
203. Sleep apnea and sleep disruption in obese patients
204. Visceral fat accumulation as an important risk factor for obstructive sleep apnoea syndrome in obese subjects
205. The relationship between neck circumference, radiographic pharyngeal anatomy, and the obstructive sleep apnoea syndrome
206. Do patients with obstructive sleep apnea have thick necks?
207. Differences in abnormal and neck circumferences in patients with and without obstructive sleep apnoea
208. Relationship of 30-year changes in obesity to sleep-disordered breathing in the western collaborative group study
209. Cephalometric abnormalities in non-obese and obese patients with obstructive sleep apnea
210. Relationship of obesity and disease in 73, 532 weight-conscious women
211. Incidence and risk factors for gout in white men
212. Fat distribution of overweight persons in relation to morbidity and subjective health
213. Hyperuricaemia: Relationships to body fat distribution and other components of the insulin resistance syndrome in 38-year-old healthy men and women
214. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration
215. The association of obesity with joint pain and osteoarthritis in the HANES data
216. Obesity and knee osteoarthritis. The Framingham study
217. The association of obesity with osteoarthritis of the hand and knee in women: A twin study
218. The relationship of obesity, fat distribution and osteoarthritis in women in the general population: The Chingford Study
219. Factors associated with radiographic osteoarthritis: Results from the population study of 70-year-old people in Goteborg
220. Obesity as a risk factor for osteoarthritis of the hand and wrist: A prospective study
221. Physical activity, obesity, height, and the risk of pancreatic cancer
222. Obesity, hypertension, and the risk of kidney cancer in men
223. Variations in mortality by weight among 750, 000 men and women
224. Physical activity, obesity, and risk for colon cancer and adenoma in men
225. Physical activity, obesity, and risk of colorectal adenoma in women
226. Colon cancer: A review of the epidemiology
227. Height, weight, and risk of colorectal cancer: An 18-year follow-up in a cohort of 5249 men
228. Body size and the risk of colon cancer in a large case-control study
229. Dual effects of weight and weight gain on breast cancer risk
230. Relative weight and risk of breast cancer among premenopausal women
231. Body mass index and ovulatory infertility
232. Maternal obesity and pregnancy
233. Maternal weight and pregnancy complications
234. Maternal obesity increases congenital malformations
235. Obesity and urinary incontinence in women
236. Body mass index and adult female urinary incontinence
237. Urinary incontinence in older women: Who is at risk?
238. Obesity and lower urinary tract function in women: Effect of surgically induced weight loss
239. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana
240. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): A case-control study
241. Effects of surgically induced weight loss on pseudotumor cerebri in morbid obesity
242. Gastric surgery for pseudotumor cerebri associated with severe obesity
243. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri)
244. A prospective study of aspirin use and cataract extraction in women
245. Body mass index. An independent predictor of cataract
246. A longitudinal study of body mass index and lens opacities. The Framingham studies
247. Relations of body fat distribution and height with cataract in men
248. Diabetes, hypertension, and central obesity as cataract risk factors in a black population. The Barbados Eye Study
249. Obese people who seek treatment have different characteristics than those who do not seek treatment
250. Psychological features of obesity
251. Relationships between obesity and DSM-IV major depression disorder, suicide ideation and suicide attempts: Results from a general population study
252. Binge eating disorder: Its further validation in a multisite study
253. Obese binge eaters: Affect, cognitions, and response to behavioral weight control
254. Binge eating increases with increasing adiposity
255. Group cognitive-behavioral therapy and group interpersonal psychotherapy for the nonpurging bulimic individual: A controlled comparison
256. Behavioral and neuroendocrine characteristics of the night-eating syndrome
257. Health-related quality of life in obese persons seeking treatment
258. Estimated economic costs of obesity in U.S. business
259. The economic costs associated with body mass index in a workplace
260. Long-term effects of change in body weight on all-cause mortality. A review
261. Prospective study of intentional weight loss and mortality in never-smoking overweight U.S. white women aged 40-64 years
262. Prospective study of intentional weight loss and mortality in overweight weight white women aged 40-64 years
263. Intentional weight loss and mortality among overweight individuals with diabetes
264. A review of the long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity
265. Beneficial health effects of modest weight loss
266. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: The SOS Intervention Study
267. Can sustained weight loss in overweight individuals reduce the risk of diabetes mellitus?
268. Clustering of metabolic factors and coronary heart disease
269. The effect of weight reduction on left ventricular mass
270. Assessment of cardiac function in patients who were morbidly obese
271. Effect of weight loss on left ventricular mass in nonhypertensive morbidly obese patients
272. Improvement of left ventricular morphology and function in obese subjects following a diet and exercise program
273. Relief of cardiorespiratory symptoms and increased physical activity after surgically induced weight loss: Results from the Swedish Obese Subjects study
274. Weight loss and progression of early atherosclerosis in the carotid artery: A four-year controlled study of obese subjects
275. Long-term effects of modest weight loss in type II diabetic patients
276. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus
277. Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus
278. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study
279. Differentiated long-term effects of intentional weight loss on diabetes and hypertension
280. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
281. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
282. Metabolic consequences of very-low-calorie diet therapy in obese non-insulin-dependent diabetic and nondiabetic subjects
283. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses
284. Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants
285. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
286. Effects of weight reduction on blood lipids and lipoproteins: A meta-analysis
287. Two-year changes in lipids and lipoproteins associated with the maintenance of a 5% to 10% reduction in initial weight: Some findings and some questions
288. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity
289. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol
290. Effect of modest weight loss on changes in cardiovascular risk factors: Are there differences between men and women or between weight loss and maintenance?
291. Early and late effects of weight loss on lipoprotein metabolism in severe obesity
292. Long-term effects of a very low calorie diet (Nutrilett) in obesity treatment. A prospective, randomized, comparison between VLCD and a hypocaloric diet + behavior modification and their combination
293. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II
294. Long-term weight loss and changes in blood pressure: Results of the trials of hypertension prevention, Phase II
295. Impact of gastric restrictive surgery on hypertension in the morbidly obese
296. The effect of gastric bypass surgery on hypertension in morbidly obese patients
297. Long-term effects of gastric surgery for treating respiratory insufficiency of obesity
298. Weight loss as a treatment for obstructive sleep apnoea
299. The effect of surgical weight reduction on sleep quality in obesity-related sleep apnea syndrome
300. Weight loss in mildly to moderately obese patients with obstructive sleep apnea
301. Effect of weight loss on upper airway collapsibility in obstructive sleep apnea
302. Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss
303. Weight reduction in osteoarthritis using phentermine
304. Effect of weight loss on musculoskeletal pain in the morbidly obese
305. Impact of weight loss on health-related quality of life
306. Swedish obese subjects (SOS) - An intervention study of obesity. Two-year follow-up of health-related quality of life (HRQL) and eating behavior after gastric surgery for severe obesity
307. Sick leave and disability pension before and after treatment for obesity: A report from the Swedish Obese Subjects (SOS) study
308. Prevalence of attempting weight loss and strategies for controlling weight
309. Three-year follow-up of the treatment of obesity by very low calorie diet, behavior therapy and their combination
310. Variability of body weight and health outcomes in the Framingham population
311. Weight cycling
312. Standard basal metabolism constants for physiologists and clinicians
313. One-year behavioral treatment of obesity: Comparison Of moderate and severe caloric restriction and the effects of weight maintenance therapy
314. A controlled trial of very-low-calorie diet, behavior therapy, and their combination in the treatment of obesity
315. Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects
316. The long term effectiveness of combined therapy by behavior modification and very low calorie diet: 2 Year follow-up
317. VLCD plus dietary and behavioral support versus support alone in the treatment of severe obesity: A randomised two-year clinical trial
318. A controlled comparison of three very-low-calorie diets: Effects on weight, body composition, and symptoms
319. Weight loss outcome and health benefits associated with the Optifast program in the treatment of obesity
320. A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients
321. Strengthening behavioral interventions for weight loss: A randomized trial of food provisions and monetary incentives
322. Food provisions vs structured meal plans in the behavioral treatment of obesity
323. Metabolic and weight loss effects of long-term dietary intervention in obese subjects
324. Metabolic and weight-loss effects of a long-term dietary intervention in obese patients: A four-year follow-up
325. Five-year self-management of weight using meal replacements: Comparison with matched controls in rural Wisconsin
326. Dietary fat intake does affect obesity!
327. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: A meta-analysis
328. The role of low-fat diets in body weight control: A meta-analysis of ad libitum dietary intervention studies
329. Randomized evaluation of a low fat "ad libitum" carbohydrate diet for weight reduction
330. A randomized trial of fat restricted versus calorie restricted diets for the treatment of obesity
331. Randomised comparison of diets for maintaining obese subjects' weight after major weight loss: Ad lib, low fat, high carbohydrate diet vs fixed energy intake
332. A descriptive study of individuals successful at long-term maintenance of substantial weight loss
333. Dietary approaches to the treatment of obesity
334. The effects of high and low energy density diets on satiety, energy intake, and eating time of obese and nonobese subjects
335. Covert manipulation of dietary fat and energy density: Effect on substrate flux and food intake in men eating ad libitum
336. Effect of high-fat and low-fat diets on voluntary energy intake and substrate oxidation: Studies in identical twins consuming diets matched for energy density, fiber and palatability
337. The effect of dietary carbohydrate:fat ratio on energy intake by adult women
338. The effect of covertly manipulating the energy density of mixed diets on ad libitum food intake in "pseudo free-living" humans
339. Energy density of foods affects energy intake in normal-weight women
340. Water incorporated into a food but not served with a food decreases energy intake in lean women
341. A critique of low-carbohydrate ketogenic weight reduction regimens
342. Composition of weight lost during short-term weight reduction
343. Comparative studies in obese subjects fed carbohydrate-restricted and high carbohydrate 1, 000-calorie formula diets
344. Similar weight loss with low- or high-carbohydrate diets
345. Weight-loss with low or high carbohydrate diet?
346. Effect of a low-carbohydrate, high-protein diet on dietary intake
347. Effects of a very-low-carbohydrate diet program on body weight: A pilot study
348. Evaluation of the Atkins diet: A randomized control trial
349. Meta-analysis: Effect of exercise, with or without dieting, on the body composition of overweight subjects
350. The effect of addition of exercise to a regime of dietary restriction on weight loss, nitrogen balance, resting metabolic rate and spontaneous physical activity in three obese women in a metabolic ward
351. Exercise in the treatment of obesity: Effects of four interventions on body composition, resting energy expenditure, appetite and mood
352. Effects of strength or aerobic training on body composition, resting metabolic rate, and peak oxygen consumption in obese dieting subjects
353. A meta-analysis of the effects of exercise and/or dietary restriction on resting metabolic rate
354. Physical activity in the treatment of the adulthood overweight and obesity: Current evidence and research issues
355. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise
356. Enhancing the efficacy of behavior therapy for obesity: Effects of aerobic exercise and a multicomponent maintenance program
357. A descriptive analysis of men and women who have lost significant weight and are highly successful at maintaining the weight loss
358. Maintenance of successful weight loss: Incidence and prediction
359. Maintenance and relapse after weight loss in women: Behavioral aspects
360. Correlates of weight loss and its maintenance over two years of follow-up among middle-aged men
361. Long-term maintenance of weight loss following supplemented fasting
362. Evaluation of an alternating-calorie diet with and without exercise in the treatment of obesity
363. Two-year follow-up of patients treated with a very-low-calorie diet and exercise training
364. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects
365. Exercise in a behavioral weight control programme for obese patients with type 2 (non-insulin-dependent) diabetes
366. The metabolic and psychological importance of exercise in weight control
367. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine
368. How much physical activity is needed to minimize weight gain in previously obese women?
369. Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women
370. Use of personal trainers and financial incentives to increase exercise in a behavioral weight loss program
371. Accuracy of five electronic pedometers for measuring distance walked
372. Prescribing exercise in multiple short bouts versus one continuous bout: Effects on adherence, cardiorespiratory fitness, and weight loss in overweight women
373. Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50-65 years
374. Effects of group-versus home-based exercise training in healthy older men and women
375. A comparison of lifestyle exercise, aerobic exercise, and calisthenics on weight loss in obese children
376. A comparison of lifestyle change and programmed aerobic exercise on weight and fitness changes in obese children
377. Effects of lifestyle activity vs. structured aerobic exercise in obese women: A randomized trial
378. Effects of exercise on glucose tolerance and insulin resistance
379. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus
380. The psychological effects of exercise
381. Characteristics of successful weight loss maintainers
382. Validity of reported energy intake in obese and nonobese adolescents
383. Behavioral assessment and treatment of markedly obese patients
384. Behavioural treatment of the overweight patient
385. Year-long weight loss treatment for obese patients with type 2 diabetes: Does including an intermittent very-low-calorie diet improve outcome?
386. Effects of four maintenance programs on the long-term management of obesity
387. Maintenance strategies for the treatment of obesity: An evaluation of relapse prevention training and postreatment contact by telephone and mail
388. Improving the long-term management of obesity: Theory research and clinical guidelines
389. Lifestyle intervention in overweight individuals with a family history of diabetes
390. Using Internet technology to deliver a behavioral weight loss program
391. Sibutramine produces dose-related weight loss
392. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
393. Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication
394. Sibutramine - A review of clinical efficacy
395. Predictors of therapeutic success with dexfenfluramine
396. Effect of sibutramine on weight maintenance after weight loss: A randomised trial
397. Behavior therapy and pharmacotherapy for obesity
398. Benefits of lifestyle modification in the pharmacologic treatment of obesity: A randomized trial
399. Current and potential drugs for treatment of obesity
400. Evaluation of drugs for treating obesity
401. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs
402. Phenylpropanolamine and the risk of hemorrhagic stroke
403. Thermogenic effects of sibutramine in humans
404. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin
405. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers
406. Lipase inhibition: A novel concept in the treatment of obesity
407. Hydrolysis of dietary fat by pancreatic lipase stimulates cholecystokinin release
408. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers
409. Comparison of continuous and intermittent anorectic therapy in obesity
410. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity
411. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: A 1-year, double-blind, placebo-controlled, multicenter trial
412. Long-term weight loss with sibutramine. A randomized controlled trial
413. Long-term maintenance of weight loss after a very low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine
414. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat
415. One year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor
416. Orlistat in the long-term treatment of obesity in primary care settings
417. Role of orlistat in the treatment of obese patients with type 2 diabetes
418. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study
419. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1-year study
420. Orlistat inhibits dietary cholesterol absorption
421. Fat intake and food choices during weight reduction with diet, behavioural modification and a lipase inhibitor
422. Gastrointestinal side effects of orlistat by concomitant prescription of natural fibers (psyllium mucilloid)
423. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β-carotene in healthy volunteers
424. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers
425. Reduction in blood cyclosporin concentrations by orlistat
426. Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes
427. Co-administration of orlistat and cyclosporine in a heart transplant recipient
428. Mode of action of orlistat
429. Influence of orlistat on the regulation of gallbladder contraction in man. A randomized double-blind placebo-controlled crossover study
430. Lack of effect of lipase inhibition with orlistat on colon cell turnover in obese subjects
431. Gastrointestinal surgery for severe obesity: Consensus Development Conference Panel
432. Long-limb gastric bypass in the superobese. A prospective randomized study
433. Stomal complications of gastric bypass: Incidence and outcome of therapy
434. Wernicke's encephalopathy after gastroplasty for morbid obesity
435. Morbid obesity, gastric plication and a severe neurological deficit
436. Vitamin and mineral deficiencies following obesity surgery
437. Vitamin B-12 deficiency after gastric surgery for obesity
438. Prophylactic iron supplementation after Roux-en-Y gastric bypass: A prospective, double-blind, randomized study
439. Survey of vitamin and mineral supplementation after gastric bypass and biliopancreatic diversion for morbid obesity
440. Vertical banded gastroplasty for obesity
441. Vertical ring gastroplasty for morbid obesity. Five year experience with 1, 463 patients
442. Results of the surgical treatment of obesity
443. A randomized prospective trial of gastric bypass versus vertical banded gastroplasty and their effects on sweets versus non sweets eaters
444. Gastric surgery for morbid obesity. The Adelaide study
445. Gastric bypass and vertical banded gastroplasty: A prospective randomized comparison and 5-year follow-up
446. Gastric surgery for morbid obesity. Complications and long-term weight control
447. Weight loss and dietary intake after vertical banded gastroplasty and Roux-en-Y gastric bypass
448. The weight reduction operation of choice: Vertical banded gastroplasty or gastric bypass?
449. Surgically induced weight loss: Gastric bypass versus gastroplasty
450. Long term prospective follow-up (> 10 years) after vertical banded gastroplasty (VBG)
451. Changes in eating behavior after horizontal gastroplasty and Roux-en-Y gastric bypass
452. Weight loss with vertical banded gastroplasty and Roux-en-Y gastric bypass for morbid obesity with selective versus random assignment
453. Laparoscopic adjustable gastric banding
454. High failure rate following laparoscopic adjustable silicone gastric banding for treatment of morbid obesity
455. Treatment of morbid obesity with the Swedish adjustable gastric band (SAGB): Complication rate during a 12-month follow-up period
456. Laparoscopic adjustable gastric banding - A caution
457. Surgical treatment of obesity
458. Results of jejunoileal bypass in two hundred patients with morbid obesity
459. Jejunoileal bypass for morbid obesity. Late follow-up in 100 cases
460. Rheumatoid arthritis associated with jejunoileal bypass
461. Renal damage after intestinal bypass
462. Hepatic steatosis after intestinal bypass-prevention and reversal with metronidazole, irrespective of protein-calorie malnutrition
463. Bypass enteropathy: An inflammatory process in the excluded segment with systemic complications
464. Reanastomosis after jejunoileal bypass
465. Biliopancreatic diversion
466. Conversion of proximal to distal gastric bypass for failed gastric bypass for superobesity
467. Reversals on 504 biliopancreatic surgeries over 12 years
468. Malabsorption procedure in surgical treatment of morbid obesity
469. Biliopancreatic diversion with duodenal switch
470. Biliopancreatic diversion (duodenal switch procedure)
471. Laparoscopic gastric bypass, Roux-en-Y 500 patients: Technique and results, with 3-60 month follow-up
472. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity
473. Laparoscopic versus open gastric bypass: A randomized study of outcomes, quality of life, and costs
474. Prospective evaluation of roux-en-Y gastric bypass as primary operation for medically complicated obesity
475. Risk reduction in gastric operations for obesity
476. Gastric bypass for treating severe obesity
477. Risks and benefits of gastric bypass in morbidly obese patients with severe venous stasis disease
478. Greater risk of incisional hernia with morbidly obese than steroid dependent patients and low recurrence with prefascial polypropylene mesh
479. Morbid obesity. Second gastric operations for poor weight loss
480. Gastric bypass revision: Lessons learned from 920 cases
481. Hairballs or haircasts of stomach and gastrointestinal tract
482. Treating morbid and supermorbid obesity
483. Large bowel impaction by the BioEnterics intragastric balloon (BIB) necessitating surgical intervention
484. Intragastric balloon in the treatment of super-morbid obesity
485. Gastric distention, hunger and energy intake after balloon implantation in severe obesity
486. Clinical trial of silicone-rubber gastric balloon to treat obesity
487. Welche berechtigung hat der magenvolumen reduzierungsballon zur gewichtsreduktion bei adipositas permagna?
488. Der magenvolumenreduzierungsballon zur gewichtsreduktion welche berechtigung hat diese umschritte methode?
489. Effect of the gastric balloon versus sham procedures on weight loss in obese subjects
490. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes
491. Obesity surgery: Expectations and reality
492. Successful weight loss following obesity surgery and the perceived liability of morbid obesity
493. Do physical activity and physical fitness avert premature mortality?
494. Statement on exercise. Benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association
495. Identifying patients for weight-loss treatment. An empirical evaluation of the NHLBI Obesity Education Initiative Expert Panel treatment recommendations